Beam Therapeutics Inc. (BEAM) Dividend Analysis
This company has no dividend history.
Based on TTM and annual data · Not a buy/sell signal
This company does not pay dividends
No dividend history found in SEC filings.
Does Beam Therapeutics (BEAM) pay a dividend?
Beam Therapeutics (BEAM) has never paid a dividend. Free cash flow is currently negative, so there is no surplus to distribute. All figures are computed from company filings; this is analysis, not investment advice.
Frequently asked
Does Beam Therapeutics (BEAM) pay a dividend?+
No. Beam Therapeutics (BEAM) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.
How does Beam Therapeutics return cash to shareholders?+
It largely does not. Beam Therapeutics pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.
Could Beam Therapeutics afford to pay a dividend?+
Not currently. Beam Therapeutics's free cash flow is negative at -$373 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.
Which healthcare companies do pay dividends?+
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Beam Therapeutics.
SourceDividend analysis computed from the 10-Q filed 28 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.
Related stocks: Biological Products, (No Diagnostic Substances)
Spot a number that looks wrong? Check it in BEAM's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BEAM
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.